JP Morgan Initiates Coverage On Neurogene with Overweight Rating, Announces Price Target of $60
JP Morgan analyst Priyanka Grover initiates coverage on Neurogene (NASDAQ:NGNE) with a Overweight rating and announces Price Target of $60.
Stocks · News reference
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166
Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $180 to $166.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Neurogene 13G Filing Shows Jennison Associates Reports 11.1% Stake In Co. As Of Sept. 30
https://www.sec.gov/Archives/edgar/data/53417/000005341726000058/xslSCHEDULE_13G_X02/primary_doc.xml
Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81
Guggenheim analyst Debjit Chattopadhyay maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target from $69 to $81.